All In Biotech

Drug Trial Radar · NCT00171275

Fluvastatin in the Therapy of Acute Coronary Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Nov 2003

Primary completion

Feb 2007

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
Collaborators
Ministry of Health, Czech Republic
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.

Conditions

  • Coronary Disease
  • Myocardial Infarction

Interventions

  • FluvastatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in circulating markers of inflammation after 4 weeks and after 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.